![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Curia Italy S.r.l. Rozzano, Milano It, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
One of their significant offerings is Bromocriptine mesilate, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2000-151 - Rev 07
This Chemical Type CEP, issued on August 05, 2021, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 596 associated with this CEP further emphasizes